25 November 2025 in American Journal of Case Reports
BACKGROUND Branch retinal vein occlusion (BRVO) is a common cause of vision loss in older adults, and cystoid macular edema (CME) is its most frequent vision-threatening complication. Depending on severity, vitreomacular traction (VMT) is typically managed with observation or surgery. When CME develops during observation (e.g., in BRVO), the therapeutic approach becomes more complex. Anti-vascular endothelial growth factor (VEGF) therapy is a standard treatment for CME secondary to BRVO. Although full-thickness macular hole (FTMH) formation is rare, it has been reported in eyes with preexisting VMT, suggesting a contributory role for tractional forces. CASE REPORT A 72-year-old woman under observation for VMT developed BRVO with CME. Baseline optical coherence tomography revealed VMT, an epiretinal membrane, a lamellar macular hole, and a vertical hyperreflective line at the fovea resembling the "foveal crack sign". The patient received an intravitreal faricimab injection to achieve rapid edema resolution with fewer injections. CME improved; however, an FTMH subsequently developed, accompanied by a decline in best-corrected visual acuity to 20/33. The patient then underwent combined vitrectomy and cataract surgery, which achieved successful hole closure. CME recurred postoperatively but responded well to a second faricimab injection, resulting in visual recovery to 20/22. CONCLUSIONS FTMH may develop after anti-VEGF therapy in eyes with preexisting VMT. This appears to be the first reported case following faricimab treatment for BRVO-associated CME, underscoring the need for careful pretreatment evaluation of the vitreoretinal interface and awareness of potential tractional complications. Individualized treatment strategies may help reduce such risks and improve outcomes.
24 October 2021 in Journal of Diabetes Investigation
Aims/Introduction Inhibition of peroxisome proliferator-activated receptor gamma (PPARγ) phosphorylation mediated by cyclin-dependent kinase 5 (Cdk5) is one of the main mechanisms of action of antidiabetic drugs. In this study, we analyzed the ocular expression and activation of Cdk5 in patients with proliferative diabetic retinopathy (PDR). Materials and Methods The concentrations of PPARγ, Cdk5, and its activating subunit (p35) were determined in the vitreous body of 24 PDR and 63 control eyes by enzyme-linked immunosorbent assay. In addition, the mRNA and protein expression levels of PPARγ, Cdk5, and p35 were measured in proliferative neovascular membranes from seven PDR eyes and non-neovascular epiretinal membranes from five control eyes by quantitative real-time polymerase chain reaction and immunohistochemical analysis. Results PPARγ, Cdk5, and p35 concentrations in the vitreous body were significantly higher in the PDR group compared with the control group. There was also a positive significant correlation of Cdk5 with PPARγ and p35 in the PDR group. Furthermore, the mRNA expression levels of PPARγ, Cdk5, and p35 in proliferative neovascular membranes were significantly higher in the PDR group compared with the control group. Immunostaining revealed increased protein expression levels of PPARγ, Cdk5, and p35 in proliferative neovascular membranes in the PDR group compared with the control group. Conclusions Cdk5 activation is involved in PDR pathogenesis via PPARγ expression, and inhibition of Cdk5-mediated PPARγ phosphorylation may be a new therapeutic target for treatment of PDR.
8 October 2025 in Journal of the American Geriatrics Society
21 July 2026 in Ophthalmology Retina
29 April 2026 in American Journal of Case Reports
Hemolytic Glaucoma Following Intravitreal Aflibercept Injection for Age-Related Macular Degeneration: A Case Report - Article abstract #952247
12 September 2026 in American Journal of Ophthalmology